Skip to main content

Table 3 Risk factors associated with the Pfdhfr intermediate-to-high resistance

From: Recent uptake of intermittent preventive treatment during pregnancy with sulfadoxine–pyrimethamine is associated with increased prevalence of Pfdhfr mutations in Bobo-Dioulasso, Burkina Faso

Variable N ≥2 Pfdhfr mutations (%) Adjusted OR (95% CI)a P value
Time between last SP dose and the survey
 No IPTp-SP 52 32 (61.5) 1  
 Early IPTp-SP 19 10 (52.6) 0.61 (0.20–1.86) 0.38
 Recent IPTp-SP 30 25 (83.3) 3.45 (1.18–10.07) 0.023
  1. aMultivariable analysis using logistic regression adjusted for residence, age, and gravidity